ees Europe: The Rise of Large-Scale Storage Systems – Driving Growth in the Storage Market and an Indispensable Pillar of the Energy Transition
27.3.2025 15:52:00 CET | Business Wire | Press release
The energy transition has reached a crucial point. With increasing electricity generation from renewable sources, the need for effective grid stabilization solutions is growing. Large-scale battery storage systems play a key role. According to SolarPower Europe, the European market will grow by 30–40% annually, driven by the rise of large-scale storage. These systems will be central to discussions at ees Europe, the continent’s largest trade fair for batteries and energy storage, from 7 to 9 May 2025.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250327880309/en/

Falling installation and operating costs as well as lower prices for batteries are boosting the large-scale storage boom. © Eco Stor GmbH
Germany is experiencing rapid growth in large-scale battery storage. In early 2023, 1.4 GWh were installed, with projections of 61 GWh by 2027 and 136 GWh by 2045. A Fraunhofer study predicts 104 GWh by 2030 and 178 GWh by 2040. By the end of 2024/25, 650 battery storage inquiries totaling 226 GW had been received.
Price erosion and fast amortization
Two key factors drive the large-scale storage boom: declining installation and operating costs, mainly due to falling battery prices, and attractive revenue opportunities in balancing energy and electricity trading. Leonhard Probst from Fraunhofer ISE estimates a three-year amortization period. Given a 15-year battery lifespan, this allows 12 years of profit generation.
Industry association calls for regulatory reform
SolarPower Europe expects longer-duration storage systems (4 to 8 hours) to become standard in Europe. However, hurdles such as technical standards and storage restrictions must be addressed, according to Dries Acke, Vice President of SolarPower Europe.
Integration and flexibility
Large-scale storage systems efficiently integrate increasing renewable electricity into the grid, ensuring power availability when needed. These systems support both grid stability and overall system efficiency. For Germany, Frontier Economics estimates that by 2050, day-ahead trading alone could yield at least €12 billion in economic benefits, mainly from fuel savings and CO2 reduction.
Grid boosters ease the burden on the power grid
Grid boosters—specialized battery storage systems—help alleviate grid bottlenecks. Tennet is operating two projects where one facility absorbs excess wind power in the north while the other feeds power into the grid in the south. This approach offers a cost-effective alternative to building new power lines.
ees Forum and ees Europe Conference: Large-scale storage systems under the spotlight
At ees Forum (Hall C2, Stand C2.230) on the first day of the trade fair, visitors can attend a session on business models and applications for large-scale storage. The ees Europe Conference, running on 6 and 7 May 2025 at the International Congress Center Messe München, will focus on regulatory requirements, investor preferences, project development, market trends, and the business outlook for large-scale storage systems. Large-scale battery storage is becoming a key component of the energy transition, enabling renewable integration, grid stability, and economic benefits. With technological advancements, declining costs, and growing demand, energy storage is set to play an increasingly vital role in Europe's renewable energy landscape.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250327880309/en/

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 15:13:00 CET | Press release
If approved, BRUKINSA plus rituximab would be the first and only chemotherapy-free, BTK inhibitor-based regimen for adult patients with previously untreated mantle cell lymphomaApplication supported by Phase 3 MANGROVE data, showing a 43% reduction in the risk of progression or death versus bendamustine plus rituximabFull MANGROVE results to be presented during the Plenary Scientific Session at the 68th American Society of Hematology Annual Meeting BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of dis
Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 15:00:00 CET | Press release
This framework agreement provides all entities subject to the French Public Procurement Code with simplified access to a support alternative enabling them to control their costs, preserve their freedom of technological choice and free themselves from vendor-imposed upgrade cycles Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMw
Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 15:00:00 CET | Press release
New data in myeloproliferative neoplasms (MPNs) will include INCA033989, Incyte’s first-in-class, mutant calreticulin (mutCALR)-targeted monoclonal antibody, in first-line myelofibrosis (MF); and preclinical findings for Incyte’s next-generation mutCALR- and JAK2V617F-targeted compoundsUpdated results for INCA033989 in second-line MF and second-line essential thrombocythemia (ET) will build on previously presented datasetsLong-term Phase 1/2 data further characterize the potential of latarcibart (VGA039), an investigational Protein S-targeting antibody, as prophylaxis in adolescents and adults with von Willebrand disease (VWD)More than 30 abstracts will highlight progress across Incyte’s broader hematology portfolioIncyte will host an investor event and webcast on Saturday, December 12, 2026 from 7:30 – 9:00 p.m. CT (8:30 – 10:00 p.m. ET) Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstra
Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 15:00:00 CET | Press release
Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e
Trained Therapeutix Discovery Appoints Andrew Glass as Chief Executive Officer4.11.2026 14:41:00 CET | Press release
Trained Therapeutix Discovery ("TTxD"), a pioneering immunotherapy company founded by the Jean Boulle Group and the Heritage Group, which is developing nanomedicines to regulate innate immunity, announces the appointment of Andrew Glass as Chief Executive Officer with immediate effect. Mr. Glass has more than 20 years of leadership experience in the life sciences industry as Chief Executive Officer of Vivasure Medical and previously from over 15 years in senior leadership roles at Abbott. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104178009/en/ Andrew Glass, CEO, TTxD Following the previously announced changes to the Company’s Board earlier this year, Mr. Glass joins the Company as it transitions from preclinical stage to being a clinical-stage organisation. His expertise in developmental strategy, financing and organisational growth is focussed on expediting the delivery of the aims associated with TTxD’s proprietary
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom